^
Association details:
| Biomarker: | IDH1 mutation |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | Farydak (panobinostat) (HDAC inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
TMOD-27. Efficacy of soluble Panobinostat (MTX110) in preclinical models of adult glioblastoma
Published date:
11/09/2020
Excerpt:
We explored the therapeutic potential of MTX110 in GBM in our preclinical in vivo adult brain tumor models....in an IDH1 mutated line, MTX110 produced a significant growth delay of 23.35 days (p Value ≤ 0.018).
DOI:
https://doi.org/10.1093/neuonc/noaa215.977
